Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT02628743
- Locations
- 🇫🇷
Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE, Bron, France
🇫🇷Hôpital Raymond Poincare; Serv. Neurologie et Réanimation pédiatriques - Centre réf. neuromusculaire, Garches, France
🇫🇷Hopital Jeanne De Flandre; CIC pediatrique, Lille, France
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
- Conditions
- Solid TumorCancer of Head and NeckBreast Cancer
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT02627274
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸UCSD - Moores Cancer Center, La Jolla, California, United States
🇨🇦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Bevacizumab in Metastatic Renal Cancer
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 365
- Registration Number
- NCT02627144
Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia
- Conditions
- Renal Anemia of Chronic Kidney Disease
- Interventions
- Other: No intervention
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT02625844
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT02624986
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇩🇪Charité Research Organisation GmbH Campus-Virchow-Klinikum, Berlin, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT02624141
A Study on Rheumatoid Arthritis Patients Treated With Rituximab
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 81
- Registration Number
- NCT02622503
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02622334
- Locations
- 🇺🇸
Cornerstone Eye Care, Div of Cornerstone Health Care, High Point, North Carolina, United States
🇸🇬Singapore National Eye Centre; Glaucoma Department, Singapore, Singapore
🇺🇸New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute, New York, New York, United States
Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02622477
- Locations
- 🇩🇪
Praxis Dr. med. Wilhelm Ammenwerth, Bochum, Germany
🇩🇪Universitätsklinikum Freiburg, Abteilung Pneumologie, Freiburg, Germany
🇩🇪Kliniken der Stadt Köln gGmbH Krankenhaus Merheim, Köln, Germany
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT02622321
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Boston Childrens Hospital, Boston, Massachusetts, United States
🇯🇵Hospital of the University of Occupational and Environmental Health,Japan, Kitakyushu-shi, Japan